Prime Therapeutics and Takeda agree to outcomes-based arrangement for Hemophilia A treatment ADVATE® [Antihemophilic Factor (Recombinant)]

EAGAN, Minn. – In an effort to help assess the value of hemophilia A treatments relative to total health care costs and emergency department visits, Prime Therapeutics LLC (Prime) has finalized an arrangement with Takeda Pharmaceuticals America, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) for the factor replacement product ADVATE® [Antihemophilic Factor (Recombinant)], which is used in the treatment and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency).

Hemophilia treatment options have increased in recent years, including innovative therapies. However, these innovations come at a high price. Therefore, it is important to establish integrated medical and pharmacy benefit contracts between payers and product manufacturers on existing treatments. The arrangement between Prime and Takeda provides:

• an opportunity to assess clinical outcomes and cost implications with an existing treatment for hemophilia A,
• a health plan remuneration model based on the level of certain quantifiable medical costs associated with unsuccessful treatment under a total cost of care model.

Hemophilia is a bleeding disorder that results from a lack of the essential clotting protein called factor VIII.¹ About 80 percent of the approximate 18,000 people living with hemophilia in the United States have hemophilia A.² Arrangements such as this help Prime better evaluate what treatments may provide the best outcomes at the best costs for members and health plan clients.

“Our work since pioneering such contracts over a decade ago has been targeted and intentional – and this agreement with Takeda is no different,” said Kelly McGrail-Pokuta, vice president of trade relations and strategy and chief trade relations officer at Prime. “Members with hemophilia need treatments that work for them at a reasonable price, and that’s exactly what drives this collaboration.”

“Takeda has a rich heritage of serving patients and providing innovative medicines to those who need them. This agreement with Prime will help us continue to deliver on our promise to provide critically important treatments with personalized care approaches to fit each patient’s needs, and to demonstrate the treatment’s overall value,” said Richard Ascroft, senior vice president managed markets and patient services at Takeda.

---

1. National Hemophilia Foundation. “Fast Facts.” National Hemophilia Foundation website. Available here: https://www.hemophilia.org/About-Us/Fast-Facts. Last accessed October 2020.
2. National Hemophilia Foundation. “Frequently Asked Questions About Hemophilia.” National Hemophilia Foundation website. Available here: https://www.hemophilia.org/walk/docs/NHFFAQs.pdf. Last accessed October 2020.